Background: There is a significant long-term burden on survivors after acute respiratory distress syndrome, even 5 years after discharge. This is not well investigated in patients treated with extracorporeal membrane oxygenation. The objective of this study was to describe very-long-term (⩾3 years) disability in lung function and morphology, quality of life, mood disorders, walking capacity, and return to work status in extracorporeal membrane oxygenation survivors. Methods: Single-center retrospective cohort study on long-term survivors treated with extracorporeal membrane oxygenation for respiratory failure between 1995 and 2010 at a tertiary referral center in Sweden. Eligible patients were approached, and those who consented were interviewed and investigated during a day at the hospital. Results: A total of 38 patients were investigated with a median follow-up time of 9.0 years. Quality of life was reduced in several Short form 36 (SF-36) subscales and all domains of the St George's Respiratory Questionnaire, similar to previous studies in conventionally managed acute respiratory distress syndrome survivors. A reduced diffusion capacity of carbon monoxide was seen in 47% of patients, and some degree of residual lung parenchymal pathology was seen in 82%. Parenchymal pathology correlated with reductions in quality of life and diffusion capacity. Symptoms of anxiety and depression were seen in 22% and 14%, respectively. Conclusion: A significant long-term burden remains even 3-17 years after extracorporeal membrane oxygenation treatment, similar to conventionally managed acute respiratory distress syndrome survivors. Future prospective studies are needed to elucidate risk factors for these sequelae.
Introduction
The morbidity and mortality associated with survival after acute respiratory distress syndrome (ARDS) remain substantial. 1 Persistent long-term disabilities involve a multitude of organ systems, including the musculoskeletal system, central and peripheral nervous systems, and the lungs. 2, 3 Many of these deficits improve in the first 12-24 months after discharge, 2, 4, 5 yet some degree of mood disorder, intensive care acquired weakness, pulmonary dysfunction, and cognitive dysfunction seem to prevail even 5 years after treatment. 2, 6, 7 Extracorporeal membrane oxygenation (ECMO) is being increasingly used in patients with ARDS refractory to conventional management, especially in the adult population. 8 The aim of ECMO treatment is to allow the lungs to rest while providing sufficient gas exchange to keep the patient alive while recovering. ECMO treatment may improve survival in the most severely ill 9, 10 and has the potential to reduce ventilatorinduced lung injury, 11 but these patients often have a longer period of immobilization and longer ICU stays, along with a higher risk of thromboembolic and bleeding complications. 3 A recent systematic review demonstrated that ECMO-treated patients, compared with conventionally managed controls, scored modestly higher on Short form 36 (SF-36) quality of life scores. 12 ECMOtreated patients had similar reductions in lung function and a lower prevalence of anxiety and depression. This included two prospective studies with relevant control groups, treated a median of 12-17 months before follow-up. However, little is known about survivorship several years after ECMO treatment for respiratory failure.
The aim of this study was to describe the very-longterm (⩾3 years) health status of adult survivors after ECMO treatment for respiratory failure.
Materials and methods
Ethical approval was granted for this study (Stockholm regional ethical review board no. 2013/2258-31/1). This clinical trial is registered at clinicaltrilas.gov (NCT03031275).
Consecutive adult survivors of ECMO for respiratory failure, treated at the ECMO Center of the Karolinska University Hospital between 1995 and July 2009, were approached in January 2014. Patients living abroad (including non-Swedish citizens), and patients with a congenital mental handicap were excluded. Seven patients treated for H1N1 influenza between July 2009 and January 2010 had already been partly investigated in 2012-2013, 3 years after treatment. 13 In these patients, the study protocol was completed for missing investigations only. Cognitive results from the present cohort have been described previously. 6 Included patients underwent the same study protocol during a day at the hospital (Table 1) . This included a clinical interview, high-resolution computed tomography (HRCT) of the thorax, pulmonary function testing, 14, 15 and a 6-minute walk test (6MWD 16 ). Selfreported quality of life was investigated using the SF-36 [17] [18] [19] and the St George' s Respiratory Questionnaire (SGRQ 20, 21 ). Anxiety and depression were assessed with the Hospital Anxiety and Depression Score 23, 24 and symptoms of posttraumatic stress disorder (PTSD) were evaluated with the Trauma Screening Questionnaire. 26 Patient charts were reviewed for relevant clinical information. Spirometry results were interpreted using a standardized algorithm, 29 with the modification that only classifies patients as having obstructive disease if FEV 1 was <80% of that predicted (in addition to the proposed FEV1/FVC <70%). All investigators were blinded from patient details but were aware of exposure to ECMO.
All patients were treated at the ECMO Center of the Karolinska University Hospital in Stockholm, Sweden. This department is a specialized tertiary referral Intensive Care Unit which only treats ECMO patients and has treated 1100 patients since 1987 (December 2018; [27] [28] [29] [30] ). Ventilator pressures and fraction of inspired oxygen were generally reduced within 3 hours from the commencement of ECMO in order to prevent further ventilator induced lung injury and were maintained until ECMO discontinuation (Supplementary Table 3 ). Sedation was kept at a minimum and the patients were generally awake, triggering their own pressure supported breaths. 22, [30] [31] [32] 
Statistical analyses
Data are reported as n (%), median values (interquartile range, IQR), or mean values (SD). Spearman's ranking correlation test was used for evaluation of correlations. Statistics were evaluated by MS Excel (Microsoft Corporation, Redmond, Washington USA) and Graph Pad Prism version 5.04 (Graph Pad Software Inc. San Diego, USA).
Results
A total of 164 patients were treated during the study period ( Figure 1 ). In all, 31 of 50 eligible long-term survivors (62%) agreed to participate. An additional 7 patients were added from the aforementioned study on H1N1 influenza patients, 13 resulting in a total cohort of 38 (further outlined in von Bahr et al. 6 ).
Median follow-up time in all patients was 9.0 years (range 3.1-17.1 years). Of the patients, 71% were treated with venovenous ECMO, 82% were treated for bacterial or viral pneumonia, and 74% (28/38) had at least one comorbidity. Data on demographics and clinical characteristics are shown in Table 2 . All investigated patients were walking without aid, had an SpO 2 > 95% at rest and were living at home without supplemental oxygen. Of them, 32% had received medical treatment for pneumonia or some other airway infection since discharge Six-minute walk test (6MWD; distance walked over a span of 6 minutes, tested by a physiotherapist).
Exercise capacity estimation and pulse oximetry oxygen saturation measurement during physical exercise.
<80% of predicted 16 or an oxygen saturation of <88% was considered pathological. Respiratory disease-specific health-related quality of life.
Three domain scores and one total score 0 to 100, with higher scores indicating worse health status. Symptoms (breathlessness, cough, and wheeze), activities (that are limited by the symptoms), and impacts (social and psychologic effect), combined in a total score.
Patient self-reported. Originally developed for chronic obstructive disease but used previously in this population. 9, 22 Hospital Anxiety and Depression Scale (HADS, Swedish version 23, 24 ).
Screening for symptoms of anxiety and depression.
Score range 0-21 for anxiety and depression, respectively. Scores of 8-10 indicate the possibility of anxiety or depression, and 11 and above indicate that these are likely to be present.
Patient self-reported. Contains 14 statements, scoring 0-3. Validated for ICU patients. 25 Trauma Screening Questionnaire (TSQ, Swedish version 26 ).
Screening for symptoms of posttraumatic stress disorder (PTSD).
Score range 0-10. Scores ⩾6 indicate possible PTSD.
Patient self-reported (yes/no). Assesses the presence of five intrusion items (e.g. upsetting dreams) and five hyperarousal items over the past week. 27 and 24% received pulmonary inhalation drugs at follow-up (13% before ECMO). All patients received conventional mechanical ventilation prior to ECMO, seven patients (19%) for more than 7 days.
A total of 51% of the patients had returned to work or studies 1 year after discharge. At follow-up, 22% (8/37) were still not in employment, six of whom had worked before ECMO (Table 3) , while 24% (8/33) had a 6MWD below 80% of expected.
Quality of life and mood disorders
A reduced physical and mental quality-of-life estimated by the SF-36 was seen in several patients, comparable to previously reported results (Figures 2-3(a) , Table 3 ). A reduced pulmonary-specific quality of life was seen in all three domains of the SGRQ (Figure 3(b) ). Individual results are presented in Supplementary Figures 1 and 2 , and descriptive statistics are presented in Supplementary  Table 1 . There was a strong correlation between the SF-36 physical component score and the SGRQ total score (Supplementary Figure 3) . Symptoms of posttraumatic stress were seen in 14% (5/36). Possible anxiety and depression were seen in 22% (8/36) and 14% (5/36), respectively (Supplementary Figure 4) , and were probable in 11% and 3%, respectively. A total of 38% had been medically treated for depression or anxiety after discharge, half of which were still treated at followup. Normal results on both questionnaires and no selfreported depression or anxiety any time after discharge were seen in 53% (19/36) .
Pulmonary morphology and function
Lung function was normal in 37% (14/38) of the patients, primarily obstructive in 13% (n = 5), and restrictive in 21% (n = 8). The remaining 29% (n = 11) had a mixed pattern or signs of a pulmonary vascular disorder (indicated by a reduced diffusion capacity (DLCO), Supplementary Table 2 ). All five patients with signs of obstruction had risk factors for obstructive lung disease (>10 pack years smoking history n = 3, asthma diagnosis n = 2). Of the eight patients with signs of restriction, three had a body mass index (BMI) >30 at the time of spirometry, and three had >10% parenchymal damage. Diffusion across the blood-gas barrier (DLCO) was reduced in 47% (18/38) . Individual results are presented in Supplementary Figure 5 , and ventilation during the first days of ECMO treatment is shown in Supplementary Table 3 .
The dominating residual pathology on HRCT, seen in 30 of the 37 tested patients (81%), was a reticular pattern in combination with parenchymal distortion that was taken to represent interstitial fibrosis and/or Table 2 ). The mean total extent of pathological parenchyma was 7% (range 0-44%). Seven patients (19%) had normal or close to normal HRCT findings, with less than 1% pathological parenchyma. A diffuse distribution was seen in 44% of the alterations observed, while involvement of the anterior lung fields predominated in 50% of patients and the posterior fields in 6% (Supplementary Figures  6-7) . Parenchymal damage correlated with days on ECMO and total days with mechanical ventilation (Spearman's rank correlation r = 0.55, p < 0.001, and r = 0.72, p < 0.001, respectively), and with SF-36 physical component score, SGRQ total score, and DLCO ( Supplementary Figures 8-10 , Spearman's rank correlation r = -0.47, p = 0.004, r = 0.57, p < 0.001, and r = -0.57, p < 0.001, respectively).
Discussion
This study investigated pulmonary morphology, function, and quality-of-life in 38 long-term survivors a median of 9 years after ECMO treatment for respiratory failure. Quality of life was reduced in most domains compared to healthy controls but was similar to previous reports. Approximately half of the patients reported anxiety, depression, or signs of PTSD some time after ECMO. Pulmonary dysfunction was common, most notably a reduced diffusion capacity was seen in 47% of patients. Some degree of residual lung parenchymal pathology was seen in 81% of the patients. To our knowledge, this is the first follow-up study investigating these parameters in ECMO-treated patients more than 3 years after discharge. Long-term disability after ARDS is well described. Davidson et al. 33 reported a significant reduction in quality of life (SF-36 and SGRQ) in ARDS patients compared with non-ARDS ICU controls in a 23-month follow-up in 1999. Herridge et al. 2 performed a longitudinal study on conventionally managed ARDS patients, including 1-5 years follow-up data. The latter patients had persistent long-term exercise limitations, reduced physical quality of life, and continuing healthcare utilization even 5 years after discharge. A wide range of psychological issues were also reported both in patients and caregivers, and 51% reported physician-diagnosed depression, anxiety, or both in the follow-up period. Interestingly, there was an improvement in all subscales of the SF-36 with each year, especially in young patients (unpublished data provided by the author), but despite this, some degree of irreversible physical dysfunction was seen. Included patients had moderate to severe disease at a time when ECMO was not readily available at the treatment center and may well have been candidates for ECMO today. A recent systematic review summarized six studies including meta-analyses of three studies which compared ECMO treated patients with non-ECMO treated ARDS controls. The two most recent of these articles reported a somewhat better quality of life in ECMO patients (CESAR study: all domains except role-emotional, 9 Luyt et al.: 3 all domains except general health), and a lower incidence of depression and anxiety. 12 The third article was published in 1998 (Stoll et al. 34 ) and reported very low SF-36 scores overall, with worse quality of life in most domains for ECMO-treated patients. The review also reported similar lung function and a significantly (and equally) reduced DLCO in both groups (in median 72-73% of normal values for both groups 12 months after treatment; this study 79%). Few studies have however reported these outcome parameters more than 3 years after ECMO.
In this study, mean SF-36 and SGRQ results were comparable to previously published data on ARDS patients. 2, 33 Patients treated with ECMO for 10 days or more were consistently over-represented in the lower ends of SF-36, SGRQ, and anxiety/depression scores ( Figure 2 and Supplementary Figures 1, 2, and 4) . These patients likely represent complicated cases with severe illness that did not rapidly improve despite ECMO 20 b Data representing patient reported occupation status after discharge from hospital. c Patients 1-3: Preterm retirement due to poor health (57, 58, and 59 years old). Patient 4: Back to unemployment, unemployed before ECMO (43 years old). Patient 5: Back to long-term sick leave, same as before ECMO (27 years old. Before severe illness requiring ECMO the patient suffered from complications to gastric bypass surgery with many re-operations. After ECMO also repeated pneumonias). Patients 6-8: Tried but failed part-time work due to poor health (43, 52 and 53 years old). d Two had retired, one was in medical rehabilitation, and two were receiving disability pension. e Two patients reached retirement age and did not return to work. f Of the eight patients with <80% of predicted 6MWD, four had risk factors for lung disease (>10 years of smoking exposition n = 2, one of which was currently smoking; active smoker n = 1; asthma and bronchiectasis n = 1).
treatment, and may have suffered from prolonged sedation, mechanical ventilation (before, during, and after ECMO) and intensive care stays. Likewise, return to work status and 6MWD were similar to what has previously been reported in ARDS patients, 2, 22 but no patients desaturated during the walk test in the present cohort, and the distance walked was modestly longer. Lindén et al. 22 reported functional outcomes at a median of 23 months after ECMO, with patients treated at our center. Most patients had limited residual parenchymal changes, and DLCO was reduced in 65% of the patients (defined as <80% of predicted normal value; this study 47%). This may represent irreversible pulmonary vascular disease and is consistent with previous reports. 12 The authors presented mean spirometry lung volumes, which have been used in several studies. 2, 3, 9 This may be misleading since there is a large spread of results, some with pathologically increased lung volumes and some with decreases (see Supplementary Figure 5 ). Lindén did not find the typical anterior localization of lung parenchymal abnormalities presumed to indicate ventilator-induced lung injury (VILI). In this study, 50% of the patients showed predominantly anterior changes, possibly indicating VILI (Supplementary Figure 7) , and 81% of the patients had some degree of parenchymal damage. There was a trend toward a lower quality of life and DLCO in patients with parenchymal damage (Supplementary Figures 8-10 ). Several patients with abnormal lung function results had non-ECMOrelated risk factors (e.g. heavy smoking), emphasizing the importance of reporting patient background data as much as is reasonably possible.
Score comparisons between studies should be undertaken with caution, given the different methods, (heterogeneous) cohorts, and follow-up times. For SF-36 and SGRQ, clinically minimal important differences for changes within a patient over time have been reported and represents the smallest score difference that patients or clinicians perceive as important. 35 It is, however, less well-studied how mean differences between groups should be interpreted, 17,36 although a score difference of 5 for SF-36 and 4 for SGRQ has been suggested. 17, 33, 36 SF-36 subscore results are non-continuous and stepwise and differ between individual domains. The results presented by Davidson 33 and Stoll 34 were reported decades ago with the intensive care treatment of the time, and before the lung-protec- tive mechanical ventilation era. 37 Furthermore, the definition of ARDS has changed over time. 1 Patients eligible for respiratory ECMO treatment are generally all in the severe ARDS category and have tried but failed conventional treatment methods, but ARDS may be misdiagnosed 38 and we could not present Berlin definition coherence in the present cohort.
This study has a risk of selection bias, given that 23 patients died after discharge and 19 of the approached survivors did not participate. Given the long follow-up time, investigated patients may have adapted to some disability and overestimated some aspects of their selfreported wellbeing. Retrospective questionnaires may be prone to subjective interpretation and colored by an individual' s memories of the events. Some patients in the present cohort were treated more than 10 years ago, and several had reached an age of 65 at the time of follow-up. Both normal aging and new events in the patient's life may have had negative implications on the present results. Intensive care management before, during, and after ECMO treatment has evolved since 1997 when the first included patient was treated. No trajectory of the outcomes could be presented; a longitudinal study with a matched control group would have been preferred but was beyond the scope of this study. Due to these limitations and the limited cohort size, we chose not to statistically test the reported findings further. We do, however, believe that the present results contribute to the knowledge about the general health status and disabilities many years after treatment with ECMO. Long-term studies beyond the first years after discharge are valuable since many parameters seem to improve even after 3-5 years. 4, 6 Although ECMO technology has evolved, the ventilator settings and approach to oxygenation and sedation have remained similar at our center between 1995 and 2009. 30, 32 Many patients needed years of rehabilitation after discharge, but it is encouraging to know that several patients may have a very high quality of life with minimal physical or mental sequelae, despite being severely ill some years earlier. As our knowledge grows, patient information needs to be updated to help patients and relatives identify treatable deficits in a timely manner.
In summary, survivorship after ECMO treatment for respiratory failure is associated with physical and psychological limitations, even 3-17 years after discharge, in line with conventionally managed ARDS survivors. Lung parenchymal damage may constitute a measurable risk factor for a reduced quality of life and DLCO. Future studies are needed to evaluate the present findings and to elucidate risk factors for long-term disabilities.
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